WO2006082304A3 - Nouveaux peptides interagissant avec les membres anti-apoptotiques de la famille de proteines bcl-2 et utilisations - Google Patents

Nouveaux peptides interagissant avec les membres anti-apoptotiques de la famille de proteines bcl-2 et utilisations Download PDF

Info

Publication number
WO2006082304A3
WO2006082304A3 PCT/FR2006/000206 FR2006000206W WO2006082304A3 WO 2006082304 A3 WO2006082304 A3 WO 2006082304A3 FR 2006000206 W FR2006000206 W FR 2006000206W WO 2006082304 A3 WO2006082304 A3 WO 2006082304A3
Authority
WO
WIPO (PCT)
Prior art keywords
bcl
proteins
family
novel peptides
interact
Prior art date
Application number
PCT/FR2006/000206
Other languages
English (en)
Other versions
WO2006082304A2 (fr
Inventor
Olivier Geneste
John Hickman
Jean-Christophe Rain
Original Assignee
Servier Lab
Hybrigenics Sa
Olivier Geneste
John Hickman
Jean-Christophe Rain
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab, Hybrigenics Sa, Olivier Geneste, John Hickman, Jean-Christophe Rain filed Critical Servier Lab
Priority to CA002596674A priority Critical patent/CA2596674A1/fr
Priority to JP2007553644A priority patent/JP4713597B2/ja
Priority to US11/883,400 priority patent/US7927813B2/en
Priority to EP06709202A priority patent/EP1844067A2/fr
Publication of WO2006082304A2 publication Critical patent/WO2006082304A2/fr
Publication of WO2006082304A3 publication Critical patent/WO2006082304A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention s'inscrit dans le cadre de la recherche et l'identification de nouveaux peptides interagissant avec les membres anti-apoptotiques de la famille de protéines Bcl-2 par le système du double hybride. L'invention a pour objet une méthode de criblage et d'identification de modulateurs de l'interaction protéique entre ces nouveaux peptides et les membres anti-apoptotiques de la famille de protéines Bcl-2. Les modulateurs identifiés sur la base de cette méthode sont administrés, aux patients atteints de cancers afin d'induire de la mort cellulaire programmée de type apoptotique et/ou autophagique chez ces derniers.
PCT/FR2006/000206 2005-02-01 2006-01-31 Nouveaux peptides interagissant avec les membres anti-apoptotiques de la famille de proteines bcl-2 et utilisations WO2006082304A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002596674A CA2596674A1 (fr) 2005-02-01 2006-01-31 Nouveaux peptides interagissant avec les membres anti-apoptotiques de la famille de proteines bcl-2 et utilisations
JP2007553644A JP4713597B2 (ja) 2005-02-01 2006-01-31 Ｂｃｌ−２タンパク質ファミリーの抗アポトーシスメンバーと相互作用する新規なペプチドおよびその使用
US11/883,400 US7927813B2 (en) 2005-02-01 2006-01-31 Peptides which interact with anti-apoptotic members of the Bcl-2 protein family, and uses
EP06709202A EP1844067A2 (fr) 2005-02-01 2006-01-31 Nouveaux peptides interagissant avec les membres anti-apoptotiques de la famille de proteines bcl-2 et utilisations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0500978 2005-02-01
FR0500978A FR2881430B1 (fr) 2005-02-01 2005-02-01 Nouveaux peptides interagissant avec les membres anti-apoptotiques de la famille de proteines bcl-2 et utilisations

Publications (2)

Publication Number Publication Date
WO2006082304A2 WO2006082304A2 (fr) 2006-08-10
WO2006082304A3 true WO2006082304A3 (fr) 2007-02-15

Family

ID=35335679

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2006/000206 WO2006082304A2 (fr) 2005-02-01 2006-01-31 Nouveaux peptides interagissant avec les membres anti-apoptotiques de la famille de proteines bcl-2 et utilisations

Country Status (7)

Country Link
US (1) US7927813B2 (fr)
EP (1) EP1844067A2 (fr)
JP (1) JP4713597B2 (fr)
CN (1) CN101111517A (fr)
CA (1) CA2596674A1 (fr)
FR (1) FR2881430B1 (fr)
WO (1) WO2006082304A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2118123T3 (pl) * 2007-01-31 2016-06-30 Dana Farber Cancer Inst Inc Stabilizowane peptydy p53 i ich zastosowania
CA2682174C (fr) 2007-03-28 2021-04-06 President And Fellows Of Harvard College Polypeptides cousus
KR20130099938A (ko) 2010-08-13 2013-09-06 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 거대고리
CN108929375A (zh) 2011-10-18 2018-12-04 爱勒让治疗公司 拟肽大环化合物
CA2864120A1 (fr) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Macrocycles peptidomimetiques reticules par triazole et par thioether
ES2817877T3 (es) 2012-02-15 2021-04-08 Aileron Therapeutics Inc Macrociclos peptidomiméticos
AU2013337388B2 (en) 2012-11-01 2018-08-02 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
CN107106642B (zh) 2014-09-24 2021-02-26 艾瑞朗医疗公司 拟肽大环化合物及其制剂
JP2017533889A (ja) 2014-09-24 2017-11-16 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ペプチド模倣大環状分子およびその使用
WO2016154058A1 (fr) 2015-03-20 2016-09-29 Aileron Therapeutics, Inc. Macrocycles peptidomimétiques et leurs utilisations
EP3347372A4 (fr) 2015-09-10 2019-09-04 Aileron Therapeutics, Inc. Macrocycles peptidomimétiques en tant que modulateurs de mcl-1

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2304124A1 (fr) * 1997-09-17 1999-03-25 The Walter And Eliza Hall Institute Of Medical Research Proteine bim de type bci-2 et methodes pour l'utiliser
AU2001271426A1 (en) * 2000-07-17 2002-01-30 Washington University Modulation of apoptosis
US7588914B2 (en) * 2001-11-13 2009-09-15 Burnham Institute For Medical Research Bacterial Bcl-2 domain-containing polypeptides, encoding nucleic acid molecules, and related methods
ES2262765T3 (es) * 2002-03-07 2006-12-01 Institut Pasteur Metodos para tamizar compuestos que modulan apoptosis, compuestos identificados por dichos metodos y uso de dichos compuestos como agentes terapeuticos.
WO2004052920A2 (fr) * 2002-12-12 2004-06-24 The Burnham Institute Conversion de proteines apoptotiques
FR2858621B1 (fr) * 2003-08-06 2007-09-07 Servier Lab Nouveau peptide interagissant avec bcl-xl et bcl-2
DK1680443T5 (en) * 2003-11-05 2015-02-02 Dana Farber Cancer Inst Inc Stabilized alpha-helix peptides and uses thereof

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
BOYD J M ET AL: "BIK, A NOVEL DEATH-INDUCING PROTEIN SHARES A DISTINCT SEQUENCE MOTIF WITH BEL-2 FAMILY PROTEINS AND INTERACTS WITH VIRAL AND CELLULAR SURVIVAL-PROMOTING PROTEINS", ONCOGENE, BASINGSTOKE, HANTS, GB, vol. 11, no. 9, 2 November 1995 (1995-11-02), pages 1921 - 1928, XP000575427, ISSN: 0950-9232 *
CORY SUZANNE ET AL: "The Bcl2 family: Regulators of the cellular life-or-death switch.", NATURE REVIEWS CANCER, vol. 2, no. 9, September 2002 (2002-09-01), pages 647 - 656, XP002355341, ISSN: 1474-175X *
DATABASE EMBL [online] 18 June 1998 (1998-06-18), "Rattus norvegicus Bcl-2 related ovarian death gene product BOD mRNA, complete cds.", XP002355353, retrieved from EBI accession no. EM_PRO:AF065431 Database accession no. AF065431 *
DATABASE UniProt 1 November 1997 (1997-11-01), "Zinc-finger protein DPF3 (cer-d4)", XP002355352, retrieved from UNIPROT Database accession no. Q92784 *
DATABASE UniProt 25 October 2004 (2004-10-25), "HECT, UBA and WWE domain containing protein 1 (E3 ubiquitin protein ligase URE-B1) (Mcl-1 ubiquitin ligase E3) (Mule) (ARF-binding protein 1) (ARF-BP1)", XP002355987, retrieved from UNIPROT Database accession no. Q7Z6Z7 *
DATABASE UniProt 29 March 2004 (2004-03-29), "DNA replication complex GINS protein PSF2", XP002355988, retrieved from UNIPROT Database accession no. Q9Y248 *
DATABASE UniProt 5 July 2004 (2004-07-05), "Mineral dust induced gene protein 2", XP002355989, retrieved from UNIPROT Database accession no. Q6SKS0 *
HSU S Y ET AL: "BOD (BCL-2-RELATED OVARIAN DEATH GENE) IS AN OVARIAN BH3 DOMAIN- CONTAINING PROAPOPTOTIC BCL-2 PROTEIN CAPABLE OF DIMERIZATION WITH DIVERSE ANTIAPOPTOTIC BCL-2 MEMBERS", MOLECULAR ENDOCRINOLOGY, BALTIMORE, MD, US, vol. 12, no. 9, September 1998 (1998-09-01), pages 1432 - 1440, XP001009737, ISSN: 0888-8809 *
INOHARA N ET AL: "harakiri, a novel regulator of cell death, encodes a protein that activates apoptosis and interacts selectively with survival-promoting proteins Bcl-2 and Bcl-Xl", EMBO JOURNAL, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 16, no. 7, April 1997 (1997-04-01), pages 1686 - 1694, XP002109282, ISSN: 0261-4189 *
OTTILIE S ET AL: "Dimerization properties of human BAD. Identification of a BH-3 domain and analysis of its binding to mutant BCL-2 and BCL-XL proteins", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 272, no. 49, 5 December 1997 (1997-12-05), pages 30866 - 30872, XP002238393, ISSN: 0021-9258 *
OWICKI J C: "FLUORESCENCE POLARIZATION AND ANISOTROPY IN HIGH THROUGPUT SCREENING: PERSPECTIVES AND PRIMER", JOURNAL OF BIOMOLECULAR SCREENING, LARCHMONT, NY, US, vol. 5, no. 5, October 2000 (2000-10-01), pages 297 - 306, XP009007612, ISSN: 1087-0571 *
WANG K ET AL: "BID: A NOVEL BH3 DOMAIN-ONLY DEATH AGONIST", GENES AND DEVELOPMENT, COLD SPRING HARBOR, NY, US, vol. 10, no. 22, 15 November 1996 (1996-11-15), pages 2859 - 2869, XP001053171, ISSN: 0890-9369 *

Also Published As

Publication number Publication date
JP4713597B2 (ja) 2011-06-29
EP1844067A2 (fr) 2007-10-17
JP2008528048A (ja) 2008-07-31
US20090325883A1 (en) 2009-12-31
FR2881430A1 (fr) 2006-08-04
CA2596674A1 (fr) 2006-08-10
FR2881430B1 (fr) 2010-10-22
WO2006082304A2 (fr) 2006-08-10
US7927813B2 (en) 2011-04-19
CN101111517A (zh) 2008-01-23

Similar Documents

Publication Publication Date Title
WO2006082304A3 (fr) Nouveaux peptides interagissant avec les membres anti-apoptotiques de la famille de proteines bcl-2 et utilisations
WO2006133088A3 (fr) Molecules d'interferons humains ameliorees et utilisations de celles-ci
WO2006076594A3 (fr) Anticorps et proteines de fusion fc a immunogenicite modifiee
WO2004047863A3 (fr) Produits geniques exprimes de maniere differentielle dans des tumeurs et leur utilisation
IL187168A (en) Proteins or polypeptides containing two identical nanobedis against Factor von Willebrand, methods for their preparation, medicinal preparations containing them and their use
WO2006062402A3 (fr) Hsp et arythmie supraventriculaire
BRPI0713000A8 (pt) Proteína de ligação multiespecífica de cadeia simples, composição farmacêutica e uso da referida proteína de ligação multiespecífica de cadeia simples
WO2007073509A3 (fr) Proteines d'annexine modifiee et procedes d'utilisation de ces proteines dans la transplantation d'organes
WO2006116181A3 (fr) Proteines regulatrices mediatrices des lymphocytes t et leurs utilisations
MX2010003380A (es) Proteinas de union a antigeno de factor de crecimiento tipo factor de crecimiento epidermico de union a heparina.
ATE382053T1 (de) System zur antikörperexpression und- synthese
NO20092741L (no) DR6-antagonister og anvendelse derav ved behandling av neurologiske forstyrrelser
WO2009142460A3 (fr) Corps synergique fusionné anticorps-peptide
WO2006086799A3 (fr) Reactifs de peptide specifiques au prion
WO2005016127A3 (fr) Reactifs peptidiques specifiques du prion
WO2004092210A3 (fr) Molecule
WO2007019865A3 (fr) Traitement au moyen de peptides de liaison cd4 et par rayonnements
WO2007059341A3 (fr) Modulateurs de la proteine kinase a base de pyrazolothiazole
WO2004029072A3 (fr) Molecules interagissant avec prpsc et utilisations associees
WO2003065003A3 (fr) Alterations de proteine de matrice nucleaire associees au cancer du colon et au cancer du colon avec metastase au foie, et utilisations associees
WO2008040190A8 (fr) Petits peptides pour anti-angiogenèse et utilisation de ceux-ci
WO2006047728A3 (fr) Genes bmp et proteines de fusion
WO2005026205A3 (fr) Produits geniques exprimes de maniere differentielle dans des tumeurs et leur utilisation
EP1937814A4 (fr) Anticorps protéiques anti-apoptotiques
WO2004083241A3 (fr) Proteines interagissant avec btc et utilisation de ces proteines

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006709202

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11883400

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2596674

Country of ref document: CA

Ref document number: 2007553644

Country of ref document: JP

Ref document number: 200680003805.5

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE

WWP Wipo information: published in national office

Ref document number: 2006709202

Country of ref document: EP